•
Jun 30, 2022

iRhythm Q2 2022 Earnings Report

Reported financial results with revenue exceeding expectations and record registrations in the U.S. business.

Key Takeaways

iRhythm Technologies reported a 25.6% increase in revenue to $102.1 million for the second quarter of 2022, driven by Zio XT and AT volume growth and increases in Medicare pricing. The company's gross margin improved to 68.8%.

Revenue increased by 25.6% to $102.1 million compared to Q2 2021.

Gross margin improved by 0.8 percentage points to 68.8% compared to Q2 2021.

Cash and short-term investments totaled $204.5 million as of June 30, 2022.

Full year 2022 revenue guidance raised to a range of $415 million to $420 million.

Total Revenue
$102M
Previous year: $81.3M
+25.6%
EPS
-$0.79
Previous year: -$0.59
+33.9%
Gross Margin
68.8%
Previous year: 68%
+1.2%
Gross Profit
$70.2M
Previous year: $55.3M
+27.0%
Cash and Equivalents
$101M
Previous year: $139M
-27.1%
Total Assets
$436M
Previous year: $485M
-10.2%

iRhythm

iRhythm

Forward Guidance

iRhythm projects revenue for the full year 2022 to range from $415 million to $420 million, which represents 29% to 30% growth over prior year results. Gross margin for the full year 2022 is expected to range from 68% to 69% and adjusted operating expenses are expected to range between $375 million and $385 million. Adjusted EBITDA for the full year 2022 is expected to range from negative $12.5 million to negative $17.5 million.